Eduard T. Ambarchian
Research Subjects
Eduard T. Ambarchian has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Nikolay N. Murashkin
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy
40 shared publications - Aleksander I. Materikin
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
36 shared publications - Roman V. Epishev
National Medical Research Center for Children’s Health
30 shared publications - Leonid A. Opryatin
National Medical Research Center for Children’s Health
27 shared publications - Roman A. Ivanov
National Medical Research Center for Children’s Health
25 shared publications - Vladislav V. Ivanchikov
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
18 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 23 (3) , 252-281
Current Guidelines for the Management of Patients with Food Allergy
This article summarizes current epidemiological, etiological, and clinical aspects of food allergy in children. Evidence-based approaches to diagnosis (including differential diagnosis), treatment, and prevention are presented. Practical management algorithms for patients are outlined, developed on the basis of current scientific literature and recent clinical data on food allergy.
- 23 July 2026
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 23 (3) , 252-281
Open AccessCurrent Guidelines for the Management of Patients with Food Allergy
This article summarizes current epidemiological, etiological, and clinical aspects of food allergy in children. Evidence-based approaches to diagnosis (including differential diagnosis), treatment, and prevention are presented. Practical management algorithms for patients are outlined, developed on the basis of current scientific literature and recent clinical data on food allergy.
- Open Access
- 16 July 2026
- Published by Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov in Vestnik dermatologii i venerologii
- Vol. 102 (3) , 92-98
New therapeutic opportunities for linear porokeratosis
Porokeratoses constitute a group of rare, clinically and genetically heterogeneous dermatoses characterized by abnormalities in epidermal keratinization due to pathogenic variants in genes involved in the mevalonate metabolic pathway. Treatment of porokeratosis has long been based on ablative procedures and various topical and systemic therapies, which have demonstrated very limited efficacy. The discovery of the metabolic pathway involved in the pathogenesis paved the way for a new class of topical agents, including a combination of statins and cholesterol, which demonstrate better results compared to previous treatment options. We describe a case of a rare linear form of porokeratosis in an adolescent presenting with multiple brown maculopapular lesions measuring 1 to 8 mm in diameter and having a specific structure: mild central atrophy and areas of peripheral hyperkeratosis. The diagnosis was verified histologically and by identifying a pathogenic nucleotide sequence variant at the splice site of intron 1 within the MVD gene (c.70+5GA). The disease therapy with a topical agent based on a combination of a statin and cholesterol was effective. The described clinical case is of considerable value in the context of the differential diagnosis of linear skin lesions, as well as diseases accompanied by impaired keratinization.
- 16 July 2026
- Published by Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov in Vestnik dermatologii i venerologii
- Vol. 102 (3) , 92-98
Open AccessNew therapeutic opportunities for linear porokeratosis
Porokeratoses constitute a group of rare, clinically and genetically heterogeneous dermatoses characterized by abnormalities in epidermal keratinization due to pathogenic variants in genes involved in the mevalonate metabolic pathway. Treatment of porokeratosis has long been based on ablative procedures and various topical and systemic therapies, which have demonstrated very limited efficacy. The discovery of the metabolic pathway involved in the pathogenesis paved the way for a new class of topical agents, including a combination of statins and cholesterol, which demonstrate better results compared to previous treatment options. We describe a case of a rare linear form of porokeratosis in an adolescent presenting with multiple brown maculopapular lesions measuring 1 to 8 mm in diameter and having a specific structure: mild central atrophy and areas of peripheral hyperkeratosis. The diagnosis was verified histologically and by identifying a pathogenic nucleotide sequence variant at the splice site of intron 1 within the MVD gene (c.70+5GA). The disease therapy with a topical agent based on a combination of a statin and cholesterol was effective. The described clinical case is of considerable value in the context of the differential diagnosis of linear skin lesions, as well as diseases accompanied by impaired keratinization.
- Open Access
- 18 January 2026
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (6) , 413-417
Dermocosmetics in Management of Adolescents with Acne
Acne vulgaris (AV) is one of the most common inflammatory skin disease in adolescents, characterised by negative impact on patients’ quality of life and psycho-emotional state. Acne affects approximately 85% of children and adolescents according to some data. Fortunately, now there are many safe and effective treatments for acne. Successful AV management often involves combination of medications that act on various pathological mechanisms. However, the paradigm of acne treatment is progressively focusing not only on pharmacotherapy, but also on care strategies based on proven products implementation. Traditionally, the international expert consensus on the use of dermocosmetics provides classification of active ingredients according to their mechanism of action and evidence level in relation to acne. Key active ingredients with proven efficacy include zinc, niacinamide, and many other components that have sebo-regulating, anti-inflammatory, and keratolytic effects, as well as normalise skin microbiome. It is crucial to consider individual skin phylotypes reflecting differences in sebum production, sensitivity, and barrier function when choosing modern dermocosmetics. Thus, dermocosmetics is integral part of comprehensive management of adolescents with acne, providing both therapeutic effect, and quality of life improvement.
- 18 January 2026
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (6) , 413-417
Open AccessDermocosmetics in Management of Adolescents with Acne
Acne vulgaris (AV) is one of the most common inflammatory skin disease in adolescents, characterised by negative impact on patients’ quality of life and psycho-emotional state. Acne affects approximately 85% of children and adolescents according to some data. Fortunately, now there are many safe and effective treatments for acne. Successful AV management often involves combination of medications that act on various pathological mechanisms. However, the paradigm of acne treatment is progressively focusing not only on pharmacotherapy, but also on care strategies based on proven products implementation. Traditionally, the international expert consensus on the use of dermocosmetics provides classification of active ingredients according to their mechanism of action and evidence level in relation to acne. Key active ingredients with proven efficacy include zinc, niacinamide, and many other components that have sebo-regulating, anti-inflammatory, and keratolytic effects, as well as normalise skin microbiome. It is crucial to consider individual skin phylotypes reflecting differences in sebum production, sensitivity, and barrier function when choosing modern dermocosmetics. Thus, dermocosmetics is integral part of comprehensive management of adolescents with acne, providing both therapeutic effect, and quality of life improvement.
- Open Access
- 30 November 2025
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (5) , 369-375
Combination of Netherton Syndrome and Hypopituitarism with Isolated Somatotropin Deficiency: Case Study
Background . Netherton syndrome is a genetic disease characterized by combination of ichthyosiform erythroderma, hair growth abnormalities, and severe atopic dermatitis with a high total IgE levels in the blood serum. However, beside the described “triad", patients with Netherton syndrome can have growth and physical development delays. In most cases, it is associated with severe course of the underlying condition, but in some cases, the cause of short stature is hypopituitarism with somatotropin deficiency. Case description . The patient with confirmed Netherton syndrome was hospitalized with physical development delay and short stature, as well as a severe course of the underlying disease with ichthyosiform erythroderma development. Patient was administered with IL-4/13 inhibitor, dupilumab, according to the off-label indication due to severe Netherton’s syndrome course. Additional examination has revealed comorbid hypopituitarism with isolated somatotropin deficiency. Growth hormone therapy was prescribed. As a result of such combined treatment, we have achieved significant improvement in the patient’s condition. No clinically significant adverse events have been reported during therapy. Conclusion. Physical development delay in patients with Netherton syndrome is the reason for conducting research on the short stature causes. The combination of growth hormone therapy with genetically engineered biologic drug dupilumab is effective and safe, however, it requires multidisciplinary approach to the management of such patients.
- 30 November 2025
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (5) , 369-375
Open AccessCombination of Netherton Syndrome and Hypopituitarism with Isolated Somatotropin Deficiency: Case Study
Background . Netherton syndrome is a genetic disease characterized by combination of ichthyosiform erythroderma, hair growth abnormalities, and severe atopic dermatitis with a high total IgE levels in the blood serum. However, beside the described “triad", patients with Netherton syndrome can have growth and physical development delays. In most cases, it is associated with severe course of the underlying condition, but in some cases, the cause of short stature is hypopituitarism with somatotropin deficiency. Case description . The patient with confirmed Netherton syndrome was hospitalized with physical development delay and short stature, as well as a severe course of the underlying disease with ichthyosiform erythroderma development. Patient was administered with IL-4/13 inhibitor, dupilumab, according to the off-label indication due to severe Netherton’s syndrome course. Additional examination has revealed comorbid hypopituitarism with isolated somatotropin deficiency. Growth hormone therapy was prescribed. As a result of such combined treatment, we have achieved significant improvement in the patient’s condition. No clinically significant adverse events have been reported during therapy. Conclusion. Physical development delay in patients with Netherton syndrome is the reason for conducting research on the short stature causes. The combination of growth hormone therapy with genetically engineered biologic drug dupilumab is effective and safe, however, it requires multidisciplinary approach to the management of such patients.
- Open Access
- 16 May 2025
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (2) , 90-95
Results of Emollient Therapy in a Child with Severe Atopic Dermatitis Treated with Genetically Engineered Biological Drug: Clinical Case
Background. Baseline therapy for children with severe atopic dermatitis (AD) is crucial for achieving required clinical effect, regardless the systemic treatment variants. Clinical case description. The boy, 9 years old, had complaints on widespread rashes on the body and limbs accompanied by dry skin and itching and was diagnosed with AD. Topical glucocorticoids, course of local medium wave narrowband phototherapy of 311 nm, topical calcineurin inhibitors were used in the treatment but with weak positive dynamics. Genetically engineered biological therapy was initiated due to frequent relapses and lack of disease control. No persistent improvement was noted after 10 weeks of therapy. The child was hospitalized, cyclic biological therapy was continued, topical therapy was corrected, and skin care was modified, the emollient-plus drug was prescribed. Clinically significant decrease in EASI and CDLQI indices, as well as a decrease in SCORAD and NRS scores was noted 4 weeks after treatment correction and emollients implementation. Conclusion. Emollients are mandatory in the management of children with AD (despite the disease severity) according to clinical guidelines. This clinical case confirms the feasibility of therapy with emollient-plus agents, as it was possible to achieve the correction of epidermal barrier dysfunction and significant clinical effect.
- 16 May 2025
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (2) , 90-95
Open AccessResults of Emollient Therapy in a Child with Severe Atopic Dermatitis Treated with Genetically Engineered Biological Drug: Clinical Case
Background. Baseline therapy for children with severe atopic dermatitis (AD) is crucial for achieving required clinical effect, regardless the systemic treatment variants. Clinical case description. The boy, 9 years old, had complaints on widespread rashes on the body and limbs accompanied by dry skin and itching and was diagnosed with AD. Topical glucocorticoids, course of local medium wave narrowband phototherapy of 311 nm, topical calcineurin inhibitors were used in the treatment but with weak positive dynamics. Genetically engineered biological therapy was initiated due to frequent relapses and lack of disease control. No persistent improvement was noted after 10 weeks of therapy. The child was hospitalized, cyclic biological therapy was continued, topical therapy was corrected, and skin care was modified, the emollient-plus drug was prescribed. Clinically significant decrease in EASI and CDLQI indices, as well as a decrease in SCORAD and NRS scores was noted 4 weeks after treatment correction and emollients implementation. Conclusion. Emollients are mandatory in the management of children with AD (despite the disease severity) according to clinical guidelines. This clinical case confirms the feasibility of therapy with emollient-plus agents, as it was possible to achieve the correction of epidermal barrier dysfunction and significant clinical effect.
- Open Access
- 24 December 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (6) , 516-522
Modern Management Approaches for Alopecia Areata
Alopecia areata is a chronic genetically determined inflammatory autoimmune disease damaging hair follicles and leading to temporary or persistent nonscarring hair loss. Janus kinase inhibitors have been registered for its management, it allows to personalize the therapy and increase its efficacy by relieving symptoms and positively affecting patients’ quality of life. This group of drugs is considered as the basic one for the treatment of alopecia areata severe forms. The issue of disease relapses after Janus kinase inhibitors cessation and safety of long-term therapy with such drugs are covered.
- 24 December 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (6) , 516-522
Open AccessModern Management Approaches for Alopecia Areata
Alopecia areata is a chronic genetically determined inflammatory autoimmune disease damaging hair follicles and leading to temporary or persistent nonscarring hair loss. Janus kinase inhibitors have been registered for its management, it allows to personalize the therapy and increase its efficacy by relieving symptoms and positively affecting patients’ quality of life. This group of drugs is considered as the basic one for the treatment of alopecia areata severe forms. The issue of disease relapses after Janus kinase inhibitors cessation and safety of long-term therapy with such drugs are covered.
- Open Access
- 31 October 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (5) , 376-383
Management of Generalized Vitiligo in Adolescent with Tofacitinib: Clinical Case
Background. Vitiligo is a depigmenting skin disease characterized by selective loss of melanocytes leading to development of typical white spots. There are various theories on vitiligo etiology: genetic, autoimmune, neurogenic, autoinflammatory, oxidative stress theory, and many others. Generally accepted dominant role is given to the concept of its autoimmune nature. Vitiligo management traditionally includes different methods of phototherapy, topical and systemic glucocorticoids (GC), and calcineurin inhibitors. Recently, Janus kinase inhibitors (JAK) have shown its efficacy in treatment of vitiligo. Clinical case description. 13-year-old male adolescent has complaints of hypopigmentation areas on the skin of face, trunk and limbs that appeared after active solar insolation during summer vacation. Dermatologist has determined a diagnosis of vitiligo according to clinical picture. Topical GC of the 3rd activity class were used for treatment, as well as course of local narrow-band medium-wave photodynamic therapy (311 nm, No. 30) with no significant effect. The patient was admitted to the dermatology department of Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery where therapy with JAK inhibitor, tofacitinib, was initiated due to inefficacy of previous treatment and the generalized form of the disease. Conclusion. Management of vitiligo with JAK inhibitors, in particular tofacitinib, is a promising method and it can lead to significant clinical effect with safety profile comparable to conventional therapies for this pathology.
- 31 October 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (5) , 376-383
Open AccessManagement of Generalized Vitiligo in Adolescent with Tofacitinib: Clinical Case
Background. Vitiligo is a depigmenting skin disease characterized by selective loss of melanocytes leading to development of typical white spots. There are various theories on vitiligo etiology: genetic, autoimmune, neurogenic, autoinflammatory, oxidative stress theory, and many others. Generally accepted dominant role is given to the concept of its autoimmune nature. Vitiligo management traditionally includes different methods of phototherapy, topical and systemic glucocorticoids (GC), and calcineurin inhibitors. Recently, Janus kinase inhibitors (JAK) have shown its efficacy in treatment of vitiligo. Clinical case description. 13-year-old male adolescent has complaints of hypopigmentation areas on the skin of face, trunk and limbs that appeared after active solar insolation during summer vacation. Dermatologist has determined a diagnosis of vitiligo according to clinical picture. Topical GC of the 3rd activity class were used for treatment, as well as course of local narrow-band medium-wave photodynamic therapy (311 nm, No. 30) with no significant effect. The patient was admitted to the dermatology department of Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery where therapy with JAK inhibitor, tofacitinib, was initiated due to inefficacy of previous treatment and the generalized form of the disease. Conclusion. Management of vitiligo with JAK inhibitors, in particular tofacitinib, is a promising method and it can lead to significant clinical effect with safety profile comparable to conventional therapies for this pathology.
- Open Access
- 31 October 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (5) , 356-362
Cutis Verticis Gyrata Differential Diagnosis: Clinical Case
Background. Cutis verticis gyrata is rare benign scalp disorder characterized by excessive skin and subcutaneous tissue proliferation and hypertrophy. Nowadays, there are three forms of this disease with various developmental mechanisms and associated manifestations. Clinical case description. This article presents the patient admitted with diagnosis and clinical picture of pachydermia, who underwent surgical excision of scalp abnormal tissues. However, the diagnosis of giant congenital melanocytic nevus was established according to the results of clinical examination. Later it was confirmed by histological and immunohistological studies. Moreover, pathogenic variants in the NRAS gene were not revealed. Conclusion. This case demonstrates the complexity of differential diagnosis of pachydermia that leads to careful examination of patients with morphogenetic studies of affected tissues samples.
- 31 October 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (5) , 356-362
Open AccessCutis Verticis Gyrata Differential Diagnosis: Clinical Case
Background. Cutis verticis gyrata is rare benign scalp disorder characterized by excessive skin and subcutaneous tissue proliferation and hypertrophy. Nowadays, there are three forms of this disease with various developmental mechanisms and associated manifestations. Clinical case description. This article presents the patient admitted with diagnosis and clinical picture of pachydermia, who underwent surgical excision of scalp abnormal tissues. However, the diagnosis of giant congenital melanocytic nevus was established according to the results of clinical examination. Later it was confirmed by histological and immunohistological studies. Moreover, pathogenic variants in the NRAS gene were not revealed. Conclusion. This case demonstrates the complexity of differential diagnosis of pachydermia that leads to careful examination of patients with morphogenetic studies of affected tissues samples.
- Open Access
- 30 October 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (5) , 309-315
Evaluation of Eating Behavior in Children with Psoriasis: Retrospective Cross Sectional Study
Background. Patients with psoriasis have increased thickness of visceral fat, including epicardial adipose tissue (EAT) that has wide spectrum of biological effects. Its thickness can be affected by the presence of obesity and eating behavior (EB) changes. Studying the associations between EB and markers of adipose tissue functional activity in children with psoriasis may help to better understand this variables correlations in the scope of comorbidities. Objective. Aim of the study is to analyze the relationship between Psoriasis Area and Severity Index (PASI), Children’s Dermatology Life Quality Index (CDLQI), EAT thickness, and leptin levels in pediatric patients with psoriasis and EB disorders. Methods. Retrospective cross sectional single-center study was conducted. 72 medical records of children with psoriasis (with varying body mass index level) who were examined and treated in dermatology department in the period from December 2021 to January 2024. All included patients have underwent dietician consultation and survey with DEBQ and CEBQ questionnaires, as a result predominant EB type was determined. EAT thickness (via two-dimensional echocardiography) and leptin levels were also measured. Psoriasis severity was evaluated via PASI and CDLQI indices. Patients were divided into three groups: with external, emotiogenic, and restrictive EB. The medians of the obtained values were calculated with determination of the confidence interval, all results were compared with each other via Kruskall-Wallis test. Results. Group of patients with external EB has shown following results: median EAT thickness was 2.5 mm (Q1–Q3: 2.1–2.8), median leptin level — 17.3 ng/ml (Q1–Q3: 14.4–26.4), median of PASI — 17 points (Q1–Q3: 12.5–20.5), median of CDLQI — 7 points (Q1–Q3: 4–13.5). Group of patients with emotionogenic EB has median EAT thickness of 2.2 mm (Q1–Q3: 1.85–2.55), median leptin level — 20.1 ng/ml (Q1–Q3: 14.5–23.95), median of PASI — 14 points (Q1–Q3: 12–16.5), median of CDLQI — 6 points (Q1–Q3: 3–12). Group of patients with restrictive EB has median EAT thickness of 3.4 mm (Q1–Q3: 3.1–3.9), median leptin level — 28.2 ng/ml (Q1–Q3: 26.1–33.5), median of PASI — 24 points (Q1–Q3: 21–27), median of CDLQI — 13 points (Q1–Q3: 9–21). Statistically significant (p = 0.0014) increase in PASI and CDLQI points was observed at comparison of different groups via Kruskall-Wallis test. Patients from restrictive EB group have shown higher values of EAT thickness, leptin levels, PASI, and CDLQI scores compared to patients with emotionogenic and external EB. No statistically significant differences were observed when comparing leptin levels and EAT thickness in the remaining groups. Conclusion. Patients with restrictive EB had higher PASI and CDLQI scores compared to patients with emotionogenic and external EB. No statistically significant differences were observed when comparing EAT thickness and leptin levels. Small study sample was the only research limitation.
- 30 October 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (5) , 309-315
Open AccessEvaluation of Eating Behavior in Children with Psoriasis: Retrospective Cross Sectional Study
Background. Patients with psoriasis have increased thickness of visceral fat, including epicardial adipose tissue (EAT) that has wide spectrum of biological effects. Its thickness can be affected by the presence of obesity and eating behavior (EB) changes. Studying the associations between EB and markers of adipose tissue functional activity in children with psoriasis may help to better understand this variables correlations in the scope of comorbidities. Objective. Aim of the study is to analyze the relationship between Psoriasis Area and Severity Index (PASI), Children’s Dermatology Life Quality Index (CDLQI), EAT thickness, and leptin levels in pediatric patients with psoriasis and EB disorders. Methods. Retrospective cross sectional single-center study was conducted. 72 medical records of children with psoriasis (with varying body mass index level) who were examined and treated in dermatology department in the period from December 2021 to January 2024. All included patients have underwent dietician consultation and survey with DEBQ and CEBQ questionnaires, as a result predominant EB type was determined. EAT thickness (via two-dimensional echocardiography) and leptin levels were also measured. Psoriasis severity was evaluated via PASI and CDLQI indices. Patients were divided into three groups: with external, emotiogenic, and restrictive EB. The medians of the obtained values were calculated with determination of the confidence interval, all results were compared with each other via Kruskall-Wallis test. Results. Group of patients with external EB has shown following results: median EAT thickness was 2.5 mm (Q1–Q3: 2.1–2.8), median leptin level — 17.3 ng/ml (Q1–Q3: 14.4–26.4), median of PASI — 17 points (Q1–Q3: 12.5–20.5), median of CDLQI — 7 points (Q1–Q3: 4–13.5). Group of patients with emotionogenic EB has median EAT thickness of 2.2 mm (Q1–Q3: 1.85–2.55), median leptin level — 20.1 ng/ml (Q1–Q3: 14.5–23.95), median of PASI — 14 points (Q1–Q3: 12–16.5), median of CDLQI — 6 points (Q1–Q3: 3–12). Group of patients with restrictive EB has median EAT thickness of 3.4 mm (Q1–Q3: 3.1–3.9), median leptin level — 28.2 ng/ml (Q1–Q3: 26.1–33.5), median of PASI — 24 points (Q1–Q3: 21–27), median of CDLQI — 13 points (Q1–Q3: 9–21). Statistically significant (p = 0.0014) increase in PASI and CDLQI points was observed at comparison of different groups via Kruskall-Wallis test. Patients from restrictive EB group have shown higher values of EAT thickness, leptin levels, PASI, and CDLQI scores compared to patients with emotionogenic and external EB. No statistically significant differences were observed when comparing leptin levels and EAT thickness in the remaining groups. Conclusion. Patients with restrictive EB had higher PASI and CDLQI scores compared to patients with emotionogenic and external EB. No statistically significant differences were observed when comparing EAT thickness and leptin levels. Small study sample was the only research limitation.
- Open Access
- 13 September 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (4) , 258-265
Successful Dupilumab Administration in Adolescent with Alopecia Areata and Atopic Dermatitis: Clinical Case
Background. Alopecia areata is an autoimmune disease characterized by hair loss that develops with the involvement of CD8+ T-cells of the immune system and cytokines produced by T-helper 2 cells (Th2). Efficacy of alopecia areata management is limited. The one potentially effective variant for treatment of severe forms of alopecia areata complicated with atopic dermatitis (AD) is genetically engineered biologic drug dupilumab (interleukin 4 receptor antagonist that suppresses Th2 response). Clinical case description. 11 years old boy was admitted to the dermatology department with complaints on aggravation of AD and numerous hair loss foci. Dupilumab, 300 mg, was prescribed once every 4 weeks. Severity of erythematous papular rashes significantly decreased within 9 months, as well as irritation intensity. Complete restoration of hair growth was noted in areas of former alopecia areata foci. Conclusion. Dupilumab can be effective in the management of severe forms of alopecia areata in children with comorbid AD. Clinical studies on the efficacy and safety of such therapy are needed to confirm this hypothesis.
- 13 September 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (4) , 258-265
Open AccessSuccessful Dupilumab Administration in Adolescent with Alopecia Areata and Atopic Dermatitis: Clinical Case
Background. Alopecia areata is an autoimmune disease characterized by hair loss that develops with the involvement of CD8+ T-cells of the immune system and cytokines produced by T-helper 2 cells (Th2). Efficacy of alopecia areata management is limited. The one potentially effective variant for treatment of severe forms of alopecia areata complicated with atopic dermatitis (AD) is genetically engineered biologic drug dupilumab (interleukin 4 receptor antagonist that suppresses Th2 response). Clinical case description. 11 years old boy was admitted to the dermatology department with complaints on aggravation of AD and numerous hair loss foci. Dupilumab, 300 mg, was prescribed once every 4 weeks. Severity of erythematous papular rashes significantly decreased within 9 months, as well as irritation intensity. Complete restoration of hair growth was noted in areas of former alopecia areata foci. Conclusion. Dupilumab can be effective in the management of severe forms of alopecia areata in children with comorbid AD. Clinical studies on the efficacy and safety of such therapy are needed to confirm this hypothesis.